Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice

[1]  G. Stoll,et al.  An intravascular perspective on hyper-acute neutrophil, T-cell and platelet responses: Similarities between human and experimental stroke , 2022, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  P. Pelegrín,et al.  Effective ex vivo inhibition of Cryopyrin-Associated Periodic Syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3. , 2022, Rheumatology.

[3]  G. Stoll,et al.  NLPR3 inflammasome inhibition alleviates hypoxic endothelial cell death in vitro and protects blood–brain barrier integrity in murine stroke , 2021, Cell Death & Disease.

[4]  G. Stoll,et al.  Infarct growth precedes cerebral thrombosis following experimental stroke in mice , 2021, Scientific Reports.

[5]  G. Stoll,et al.  Platelet Activation and Chemokine Release Are Related to Local Neutrophil-Dominant Inflammation During Hyperacute Human Stroke , 2021, Translational Stroke Research.

[6]  G. Stoll,et al.  Danger-associated molecular patterns are locally released during occlusion in hyper-acute stroke , 2021, Brain, behavior, & immunity - health.

[7]  G. Stoll,et al.  Validity and Efficacy of Methods to Define Blood Brain Barrier Integrity in Experimental Ischemic Strokes: A Comparison of Albumin Western Blot, IgG Western Blot and Albumin Immunofluorescence , 2021, Methods and Protocols.

[8]  G. Stoll,et al.  Platelets and lymphocytes drive progressive penumbral tissue loss during middle cerebral artery occlusion in mice , 2021, Journal of Neuroinflammation.

[9]  G. Stoll,et al.  The NLRP3 inflammasome drives inflammation in ischemia/reperfusion injury after transient middle cerebral artery occlusion in mice , 2020, Brain, Behavior, and Immunity.

[10]  G. Stoll,et al.  Beyond recanalization — a call for action in acute stroke , 2020, Nature Reviews Neurology.

[11]  C. Iadecola,et al.  Immune responses to stroke: mechanisms, modulation, and therapeutic potential. , 2020, The Journal of clinical investigation.

[12]  M. Lawton,et al.  Global brain inflammation in stroke , 2019, The Lancet Neurology.

[13]  M. Janowski,et al.  Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles , 2019, Journal of Neuroinflammation.

[14]  G. Stoll,et al.  Thrombo-inflammation in acute ischaemic stroke — implications for treatment , 2019, Nature Reviews Neurology.

[15]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[16]  S. Khoshnam,et al.  NLRP3 inflammasome in ischemic stroke: As possible therapeutic target , 2019, International journal of stroke : official journal of the International Stroke Society.

[17]  G. Stoll,et al.  Targeting Platelet GPVI Plus rt-PA Administration but Not α2β1-Mediated Collagen Binding Protects against Ischemic Brain Damage in Mice , 2019, International journal of molecular sciences.

[18]  D. Brough,et al.  Extent of Ischemic Brain Injury After Thrombotic Stroke Is Independent of the NLRP3 (NACHT, LRR and PYD Domains-Containing Protein 3) Inflammasome , 2019, Stroke.

[19]  Hemmings C. H. Wu,et al.  Gasdermin Family: a Promising Therapeutic Target for Stroke , 2018, Translational Stroke Research.

[20]  A. Vandenbark,et al.  Sex differences in regulatory cells in experimental stroke. , 2017, Cellular immunology.

[21]  C. Kleinschnitz,et al.  B cells do not have a major pathophysiologic role in acute ischemic stroke in mice , 2017, Journal of Neuroinflammation.

[22]  M. Lotze,et al.  The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation. , 2017, Biochemical and biophysical research communications.

[23]  G. Stoll,et al.  Blocking of platelet glycoprotein receptor Ib reduces “thrombo-inflammation” in mice with acute ischemic stroke , 2017, Journal of Neuroinflammation.

[24]  A. Demchuk,et al.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.

[25]  N. Plesnila,et al.  Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia , 2015, Science Translational Medicine.

[26]  Haitao Guo,et al.  Inflammasomes: mechanism of action, role in disease, and therapeutics , 2015, Nature Medicine.

[27]  R. Morita,et al.  Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury , 2015, Nature Communications.

[28]  N. Rothwell,et al.  AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3 , 2015, Proceedings of the National Academy of Sciences.

[29]  K. Tracey,et al.  DAMP Signaling is a Key Pathway Inducing Immune Modulation after Brain Injury , 2015, The Journal of Neuroscience.

[30]  Ziying Wang,et al.  NLRP3 Deficiency Ameliorates Neurovascular Damage in Experimental Ischemic Stroke , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  M. Mattson,et al.  Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke , 2013, Cell Death and Disease.

[32]  Douglas G Altman,et al.  Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  T. Schallert.  Behavioral tests for preclinical intervention assessment , 2006, NeuroRX.

[34]  T. Iwaki,et al.  Pivotal role of cerebral interleukin-17–producing γδT cells in the delayed phase of ischemic brain injury , 2009, Nature Medicine.

[35]  Christian Gerloff,et al.  Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. , 2009, Stroke.

[36]  T. Renné,et al.  Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis , 2006, The Journal of experimental medicine.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  M. Chopp,et al.  Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats , 2001, Stroke.

[40]  L. Pitts,et al.  Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.